<DOC>
	<DOCNO>NCT00004241</DOCNO>
	<brief_summary>Drugs use chemotherapy work different way stop cancer cell divide stop grow die . This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin treating patient advanced epithelial cancer , malignant lymphoma , sarcoma</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Advanced Epithelial Cancer , Malignant Lymphoma , Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) patient advanced epithelial cancer , malignant lymphoma , sarcoma . II . Determine significant toxic effect associate drug patient . III . Determine response patient treated drug . IV . Determine pharmacokinetics 17-AAG 17AG patient . OUTLINE : This dose-escalation study . Patients receive treatment accord 1 2 schedule . Schedule B : Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 1-2 hour twice weekly 3 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . Schedule C : Patients receive 17-AAG IV 1-2 hour twice weekly 2 week . Courses repeat every 3 week absence disease progression unacceptable toxicity . In schedule , cohort 3-6 patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . At least 6 patient receive treatment MTD . PROJECTED ACCRUAL : A maximum 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<criteria>Histologically confirm advanced epithelial cancer , malignant lymphoma , sarcoma standard curative therapy exist Brain metastasis allow definitive radiotherapy Performance status ECOG 02 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL SGOT great 2 time normal Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 week , , least 2 week study completion No active infection No serious concurrent condition No prior allergic reaction egg product At least 4 week since prior biologic therapy ( regional systemic ) At least 4 week since prior chemotherapy See Disease Characteristics At least 4 week since prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>